Aureka lands $100M Series B to build a biological "world model" for drug discovery
What's the deal? Aureka Biotechnologies has closed a $100 million Series B to train its next generation of biological foundation models. Granite AsiaDealroom has a profile for this one. Try Dealroom → funded the first tranche exclusively, followed by a strategic investor-led tranche with HighLight CapitalDealroom has a profile for this one. Try Dealroom → and existing backers MPCiDealroom has a profile for this one. Try Dealroom → and NRL CapitalDealroom has a profile for this one. Try Dealroom →. The round takes the AI-native TechBio company to nearly $200 million raised since its 2023 founding.
What's the endgame? Aureka wants AI models that don't just solve individual drug discovery tasks but "learn the rules of biology." The proceeds will fund large-scale model training for de novo molecular design, structure modeling, and function prediction.
Why now? The company says its closed-loop infrastructure is already built, so the focus shifts to the "intelligence core." Its Lab-in-the-Loop engine ties AI models to single-cell functional screening and high-throughput experimental validation, generating proprietary data that feeds back into training.
By the numbers: At $100 million, the round sits in the top 7% of all Series B deals in health across its country by size, drawing from a sample of 3,698 comparable rounds. That places Aureka well above the median for the sector and geography.
What could go wrong? Aureka concedes that "biology does not yield to computation alone." Its bet depends on experimental feedback continually correcting model bias — a costly, iterative loop with no guaranteed payoff in approved drugs.
The signal: Aureka reframes the pitch from using AI to make drug discovery faster to using AI to model living systems. As foundation models and automated R&D converge, the round is a sizeable wager that owning the full data-to-experiment loop — not just the algorithms — is what separates the field's contenders.
Read more: PR Newswire
Image credit: Aureka Biotechnologies
